See associations below
IHC markers
Test Code | Description |
---|---|
I AE1/AE3 | cytokeratin cocktail, PAN(AE1/AE3) |
I AFP* | alpha fetoprotein |
I ALK | anaplastic lymphoma kinase-1 |
I ANDRO | androgen receptor |
I ANXA1 | annexin A1 |
I ARG1 | Anti Arginase-1 |
I BCL2 | follicular lymphoma, apoptosis |
I BCL6 | follicle center B-cells |
I BER EP4 | epithelial antigen |
I CA125* | epitheliod malignancies ovary, breast |
I CA19-9 | pancreas, liver, ovary, lung tumors |
I CALCT* | calcitonin |
I CALDSM | caldesmon, smooth muscle |
I CALRT | calretinin; calcium binding protein |
I CAM52 | Cytokeratin CK7/CK8 |
I CATHD* | cathepsin D, breast carcinoma |
I CD1a | cortical thymocytes, Langerhans cells |
I CD2 | thymic, T-cells, NK cells |
I CD3 | pan T-cell antigen |
I CD4 | helper T-cells |
I CD5 | pan T-cell, B-cell subset, thymic carcinoma |
I CD7 | T-cell, lymphocytes |
I CD8 | suppressor T-cell |
I CD10 | common ALL antigen |
I CD15 | epithelial, myeloid, Reed-Sternberg cell |
I CD19 | pan B-cell, follicular dendritic cells, clone BT51 |
I CD20 | pan B-cell |
I CD22 | BL-CAM, Early B-cell, hairy cell leukemia, clone FPC1 |
I CD23 | activated B-cells |
I CD25 | IL-2 Receptor alpha chain |
I CD30 | Ki-1 activated T/B-cell, Reed-Sternberg cell |
I CD31 | endothelial cells |
I CD34 | endothelial, stem cells, stromal cells |
I CD42b | glycoprotein, GPIb, platelets, megakaryocytes |
I CD43 | T-cell, myeloid, B-cell subset, histiocytes |
I CD45 | leukocyte common antigen |
I CD45 RO | activated T-cells, resting |
I CD56 | NK cells |
I CD57 | neural, neuroendocrine, NK cells |
I CD61 | glycoprotein GPIIIa |
I CD68 | macrophages |
I CD79a | B-cell, plasma cells |
I CD99 | Ewings sarcoma, PNET |
I CD103 | Integrin alpha E |
I CD117 | c-kit, myeloid, mast cells, GIST |
I CD138 | plasma cells, subset epithelial cells |
I CD163 | histiocytes |
I CDK4 | cyclin-depdendent kinase-4, clone DCS-31 |
I CDX2 | colorectal carcinoma |
I CEA | carcinoembryonic antigen |
ICHROGRAN | chromogranin A |
I CK HMW | cytokeratin high mol wight; 34BE12 |
I CK5/6 | cytokeratin 5/6, squamous, mesothelial |
I CK7 | cytokeratin 7, 54kD |
I CK8* | cytokeratin 8, 35BH11 |
I CK8/18 | cytokeratin 8/18, adenocarcinoma |
I CK19* | cytokeratin 19 |
I CK20 | cytokeratin 20 |
I CLLGIV* | Collagen IV, basement membrane protein |
I CMV | cytomegalovirus |
I CYCLIN | cyclin D1/PRAD1, mantle cell lymphoma |
I D2 40 | podoplanin |
I DESMIN | desmin filament protein |
I DOG1 | derived from GIST1 |
I EBER ISH | Epstein Barr virus early RNA by ISH** |
I ECAD | E-cadherin epithelial cell, ductal-type breast |
I EMA | epithelial membrane antigen |
I ER | estrogen receptor |
I ERA | epithelial related antigen (MOC-31) |
I FOXP3 | forkhead box P3, transcription factor |
I FVIII | factor VIII Von Willebrand |
I FXIIIA | factor XIIIa fibrohistiocytic |
I GALECT* | glaectin-3, thyroid neoplasm, anaplastic LCL |
I GASTRIN* | gastrin, G-cell antral/pyloric |
I GCDFP15 | gross cystic disease fluid protein |
I GFAP* | human glial fibrillary acidic protein |
I GLYCPA | glycophorin-A |
I GRANB | granzyme B, cytotoxic T-cell subset, NK cell |
I HEPAR1 | hepatocyte antigen (HEP-Par-1) |
I HER2 | Her2/neu (IVD) |
I HER2 GA | Her2/neu, gastric |
I HHV8 | human herpes viurs type 8 |
I HMB 45 | melanoma associated marker |
I HSV | herpes simplex virus type I and type 2 |
I INHIBIN* | inhibin |
I KAP ISH | kappa immunoglobulin light chains by ISH** |
I KI67 | Cell proliferation marker |
I LAM ISH | lambda immunoglobulin light chains by ISH** |
I MAMMA | mammaglobin |
I MDM2 | E3 ubiquitin ligase, clone SMP-1 |
I MELANA | melanoma associated marker/Mart 1 |
I MPO | myeloperoxidase |
I MSA* | msa |
I MSI | microsatellite instability-MLH1/MSH2/MSH6/PMS2 |
I MUC1 | mucin glycoprotein |
I MUM1 | multiple myeloma oncogene 1 |
I MYOGEN* | myogenin muscle marker |
I MYOGLB* | myoglobin cardiac, skeletal |
I NAPA | napsin A |
I NF* | neurofilament |
I NSE | neuron-specific enolase (NSE) |
I P16 | p16 tumor suppresor protein |
I P504S | gene product (AMACR) prostatic adenocarcinoma |
I P53 | p53 tumor suppressor gene protein |
I P57 | p57KIP2 cyclin-dependant kinase, tumor suppressor gene |
I P63 | p63 tumor suppressor gene protein nuclear |
I PAX 5 | PAX-g, B-cell transcription factor |
I PD-1 | Programmed death-1 immune response marker |
I PD-L1 | PD-L1 protein, tumor prognostic marker |
I PLAP* | placental alkaline phosphatase, germ cell tumor |
I PR | progestorone receptor |
I PSA | prostate specific antigen |
I PSAP | prostatic acid phosphorase |
I PYLORI | helicobacter pylori |
I RCC | renal cell carcinoma |
I S100 | S100 protein |
I SMA | smooth muscle actin |
I SMM | smooth muscle myosin |
I SOMATO* | Somatostatin, D-cells pancreatic islet cells |
I SOX11 | sox-11, mantle cell lymphoma |
I SYNPTP | synaptophysin |
I TAG72 | adenocarcinoma, HMW glycoprotein |
I TDT | terminal deoxynucleotidyl transferase |
I THYRGLB* | throglobulin |
I TTF1 | thyroid transcription factor-1 |
I TYR | tyrosinase |
I V600E | BRAF |
I VIM | vimentin |
I VWF | von willebrand Factor VIII |
I VZV* | varicella zoster virus |
I WT1 | Wilm's tumor |
* Performed at affiliate laboratory | |
ISH** In situ hybridization | |
Updated 23FEB2017 |
Immunohistochemistry
* indicates performed by affiliate laboratory
** in-situ hybridization
Technical component (TC) available for all markers.
2 days, exception being on send out tests
Paraffin embedded tissue block
3 slides (3-5 uM) per marker on adhesion glass
Please note:
If submitting HER2 protein over-expression by immunohistochemistry,
HER2(ERBB2) gene amplification by in situ hybridization or estrogen /
progesterone receptor expression by immunohistochemistry, the specimen must
follow fixation guidelines listed below:
1. Specimens should be immersed in fixative within one hour of the biopsy or
resection.
2. If delivery of a resection specimen to the pathology department is delayed (eg,
specimens from remote sites), the tumor should be bisected prior to the
immersion in fixative. In such cases, it is important that the surgeon ensure
that the identity of the resection margins is retained in the bisected specimen;
alternatively, the margins may be separately submitted.
3. The time of removal of the tissue and the time of immersion of the tissue in
fixative should be recorded and submitted to the laboratory.
Ship ambient. Protect from extreme temperature with an ice pack. Separate ice pack from specimen.
Inadequate fixation
Improper labeling
Marker and tissue specific
Results are reviewed by a board-certified pathologist to determine if tissues are positive or negative for the marker. These results may be used to assist in determining appropriate patient therapy or treatment. Immunohistochemistry combines the principles of histochemistry with the high degree of molecular specificity of the antibody-antigen reaction. The use of an enhanced-polymer detection system provides many benefits, including increased sensitivity, fewer procedural steps as compared to conventional techniques, and a reduction in non-specific background staining. MPLN offers a range of markers by Immunohistochemistry including hematologic, tissue specific, infectious agents and proliferation antigens.
Battifora et al. (1993). Appl Immunohistochem. 1:39-45.
Perttschuk et al. (1996). Cancer. 77:2514-15.
Press M et al. (2002). Steroids. 67:799-813.